CDXS
CODEXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.36
+3.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.35
From 52W high−52.28%
Volume2.87M
Market cap$148.93M
P/E (TTM)—
P/S (TTM)1.9x
Div yield—
Key dataSep 18, 2026
Open
$1.35
From 52W high
−52.28%
Volume
2.87M
Market cap
$148.93M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.7x
P/E (TTM)
—
RSI (14)
35.9
MomentumView details →
1D Return
+3.03%
YTD Return
−17.48%
SummaryUpdated Jun 1, 2026
Codexis, Inc. (NASDAQ:CDXS) is a biotechnology company founded in 2002 and headquartered in Redwood City, California. The company went public in 2010 and specializes in developing engineered enzymes and proteins through its proprietary CodeEvolver protein engineering platform. Codexis has evolved from a broad enzyme development company to focus primarily on pharmaceutical manufacturing applications, particularly in the emerging field of small interfering RNA (siRNA) therapeutics production through its ECO Synthesis platform.
Similar companies
Latest newsMore news →
Codexis reported financial results for the second quarter ended June 30, 2026, with revenue of $14.9 million.40d agoCodexis completed an equity capital raise with approximately $25 million in net proceeds.40d agoCodexis announced a proposed underwritten public offering of shares of its common stock.59d ago